These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31307977)

  • 1. Identification of Novel Trypanosoma cruzi Proteasome Inhibitors Using a Luminescence-Based High-Throughput Screening Assay.
    Zmuda F; Sastry L; Shepherd SM; Jones D; Scott A; Craggs PD; Cortes A; Gray DW; Torrie LS; De Rycker M
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31307977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural analysis and shape-based identification of novel inhibitors targeting the Trypanosoma cruzi proteasome.
    Silva GM; Gomes SQ; Lopes CD; de Albuquerque S; de Paula da Silva CHT
    Int J Biol Macromol; 2024 Oct; 277(Pt 3):134290. PubMed ID: 39084432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a Proteasome-Targeting Arylsulfonamide with Potential for the Treatment of Chagas' Disease.
    Lima ML; Tulloch LB; Corpas-Lopez V; Carvalho S; Wall RJ; Milne R; Rico E; Patterson S; Gilbert IH; Moniz S; MacLean L; Torrie LS; Morgillo C; Horn D; Zuccotto F; Wyllie S
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0153521. PubMed ID: 34606338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
    Engel JC; Ang KK; Chen S; Arkin MR; McKerrow JH; Doyle PS
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3326-34. PubMed ID: 20547819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trypanosoma brucei: β2-selective proteasome inhibitors do not block the proteasomal trypsin-like activity but are trypanocidal.
    Steverding D; Florea BI; Overkleeft HS
    Mol Biochem Parasitol; 2019 Jan; 227():1-4. PubMed ID: 30444977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Machine Learning Models and Pathway Genome Data Base for Trypanosoma cruzi Drug Discovery.
    Ekins S; de Siqueira-Neto JL; McCall LI; Sarker M; Yadav M; Ponder EL; Kallel EA; Kellar D; Chen S; Arkin M; Bunin BA; McKerrow JH; Talcott C
    PLoS Negl Trop Dis; 2015; 9(6):e0003878. PubMed ID: 26114876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target-based Screening of the Chagas Box: Setting Up Enzymatic Assays to Discover Specific Inhibitors Across Bioactive Compounds.
    Salas-Sarduy E; Niemirowicz GT; José Cazzulo J; Alvarez VE
    Curr Med Chem; 2019; 26(36):6672-6686. PubMed ID: 31284853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-Guided Design and Synthesis of a Pyridazinone Series of
    Thomas MG; McGonagle K; Rowland P; Robinson DA; Dodd PG; Camino-Díaz I; Campbell L; Cantizani J; Castañeda P; Conn D; Craggs PD; Edwards D; Ferguson L; Fosberry A; Frame L; Goswami P; Hu X; Korczynska J; MacLean L; Martin J; Mutter N; Osuna-Cabello M; Paterson C; Peña I; Pinto EG; Pont C; Riley J; Shishikura Y; Simeons FRC; Stojanovski L; Thomas J; Wrobel K; Young RJ; Zmuda F; Zuccotto F; Read KD; Gilbert IH; Marco M; Miles TJ; Manzano P; De Rycker M
    J Med Chem; 2023 Aug; 66(15):10413-10431. PubMed ID: 37506194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel cruzain inhibitors for the treatment of Chagas' disease.
    Rogers KE; Keränen H; Durrant JD; Ratnam J; Doak A; Arkin MR; McCammon JA
    Chem Biol Drug Des; 2012 Sep; 80(3):398-405. PubMed ID: 22613098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease.
    Riley J; Brand S; Voice M; Caballero I; Calvo D; Read KD
    PLoS Negl Trop Dis; 2015 Sep; 9(9):e0004014. PubMed ID: 26394211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of novel bromodomain inhibitors of
    Tavernelli LE; Alonso VL; Peña I; Rodríguez Araya E; Manarin R; Cantizani J; Martin J; Salamanca J; Bamborough P; Calderón F; Gabarro R; Serra E
    Antimicrob Agents Chemother; 2024 Aug; 68(8):e0024324. PubMed ID: 39028190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi.
    Keenan M; Alexander PW; Chaplin JH; Abbott MJ; Diao H; Wang Z; Best WM; Perez CJ; Cornwall SM; Keatley SK; Thompson RC; Charman SA; White KL; Ryan E; Chen G; Ioset JR; von Geldern TW; Chatelain E
    Future Med Chem; 2013 Oct; 5(15):1733-52. PubMed ID: 24144410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and evaluation of substrate - analogue inhibitors of Trypanosoma cruzi ribose 5-phosphate isomerase type B.
    Gonzalez SN; Mills JJ; Maugeri D; Olaya C; Laguera BL; Enders JR; Sherman J; Rodriguez A; Pierce JG; Cazzulo JJ; D'Antonio EL
    Bioorg Med Chem Lett; 2021 Jan; 32():127723. PubMed ID: 33249135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomic and bioinformatic analysis of Trypanosoma cruzi chemotherapy and potential drug targets: new pieces for an old puzzle.
    Sadok Menna-Barreto RF; Belloze KT; Perales J; Silva FP
    Curr Drug Targets; 2014 Mar; 15(3):255-71. PubMed ID: 24041335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystal violet structural analogues identified by in silico drug repositioning present anti-Trypanosoma cruzi activity through inhibition of proline transporter TcAAAP069.
    Sayé M; Gauna L; Valera-Vera E; Reigada C; Miranda MR; Pereira CA
    PLoS Negl Trop Dis; 2020 Jan; 14(1):e0007481. PubMed ID: 31961864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotypic screening approaches for Chagas disease drug discovery.
    Chatelain E; Ioset JR
    Expert Opin Drug Discov; 2018 Feb; 13(2):141-153. PubMed ID: 29235363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development.
    Moraes CB; Giardini MA; Kim H; Franco CH; Araujo-Junior AM; Schenkman S; Chatelain E; Freitas-Junior LH
    Sci Rep; 2014 Apr; 4():4703. PubMed ID: 24736467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular design aided by random forests and synthesis of potent trypanocidal agents as cruzain inhibitors for Chagas disease treatment.
    de Albuquerque S; Cianni L; de Vita D; Duque C; Gomes ASM; Gomes P; Laughton C; Leitão A; Montanari CA; Montanari R; Ribeiro JFR; da Silva JS; Teixeira C
    Chem Biol Drug Des; 2020 Sep; 96(3):948-960. PubMed ID: 33058457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Automated high-content assay for compounds selectively toxic to Trypanosoma cruzi in a myoblastic cell line.
    Alonso-Padilla J; Cotillo I; Presa JL; Cantizani J; Peña I; Bardera AI; Martín JJ; Rodriguez A
    PLoS Negl Trop Dis; 2015 Jan; 9(1):e0003493. PubMed ID: 25615687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Parameters Impacting Drug Susceptibility in Intracellular Trypanosoma cruzi Assay Protocols.
    Yang G; Lee N; Ioset JR; No JH
    SLAS Discov; 2017 Feb; 22(2):125-134. PubMed ID: 27729503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.